



Ocera Therapeutics, Inc.
Investor Relations Department
5001 S. Miami Boulevard,
Suite 300
Durham, NC 27703
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: OCRX

Last Trade:	1.13
Trade Time:	4:00 PM ET May 26, 2017
Change:	0.00 (0.000%)
Day Range	1.12 - 1.19
52-Week Range	0.52 - 3.15
Volume	272,580


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

[Ocera Therapeutics](#)
(NASDAQ:OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 26, 2017

[Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2](#)

May 9, 2017

[Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update](#)

May 3, 2017

[Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017](#)

Apr 12, 2017

[Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease \(NAFLD\)](#)

Mar 27, 2017

[Ocera to Present at the 16th Annual Needham Healthcare Conference](#)

Upcoming Events [\[View all \]](#)

Jun 2, 2017 11:00 AM ET

[Ocera KOL Conference Call on Unmet Needs in Hepatic Encephalopathy and Other Complications of Liver Disease](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 14, 2017

[Annual Report \(10-K\)](#)

Apr 25, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 2, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)